AG百家乐大转轮-AG百家乐导航_怎么看百家乐走势_全讯网官网 (中国)·官方网站

Research News

Professor Ming Kuang's group revealed the epigenetic mechanism of lenvatinib resistance in HCC

Share
  • Updated: Oct 21, 2022
  • Written:
  • Edited: Li Tongzhou, Wang Dongmei

Recently, Prof. Ming Kuang's research team from the First Affiliated Hospital, Sun Yat-sen University published a research paper entitled “METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma” online in Cancer Research, which deciphered novel mechanisms underlying lenvatinib resistance from a translation level perspective.

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. Over 70% of HCC are diagnosed at advanced stages, with very limited treatment options. The tyrosine kinase inhibitor lenvatinib is a first-line drug for treating patients with advanced HCC. However, its efficacy is severely hampered by drug resistance. Insights into the molecular mechanisms underlying lenvatinib resistance could provide new strategies to improve and prolong responses.

Prof. Ming Kuang's research team has successfully constructed lenvatinib-resistant HCC cell lines and performed un-biased proteomic profiling. They found that METTL1 and WDR4, the two key components of the tRNA m7G methyltransferase complex, were dramatically upregulated in lenvatinib-resistant cells. Moreover, HCC organoids with higher expressions of METTL1 and WDR4 tended to be more tolerant to lenvatinib and patients with low METTL1/WDR4 level had significantly better prognosis when receiving adjuvant lenvatinib treatment.

Functionally, knockdown of METTL1 overrode resistance by impairing the proliferation capacity of HCC cells and promoting apoptosis under lenvatinib treatment. In addition, overexpression of wild-type METTL1 but not its catalytic dead mutant induced lenvatinib resistance. Animal experiments including hydrodynamic injection, subcutaneous implantation, and orthotopic xenograft mouse models further demonstrated the critical function of METTL1/WDR4-mediated m7G tRNA modification in promoting lenvatinib resistance in vivo. Mechanistically, through TRAC sequencing, RNC seuencing and polysome qPCR, they further found that METTL1 promoted translation of EGFR pathway genes to trigger drug resistance. This work reveals the important role of METTL1-mediated m7G tRNA modification in promoting lenvatinib resistance and provides a promising prediction marker and intervention target for resistance.

This work was supported by National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, GDSTC | Basic and Applied, Basic Research Foundation of Guangdong Province and China Postdoctoral Science Foundation.

Link to the article: 

https://aacrjournals.org/cancerres/article-abstract/doi/10.1158/0008-5472.CAN-22-0963/709196/METTL1-mediated-m7G-tRNA-modification-promotes?redirectedFrom=fulltext


TOP
玩百家乐技巧博客| bet365体育在线投注 jxhymp| 百家乐官网娱乐网会员注册 | 网球比赛比分直播| 百家乐玩法简介| 大发888网址官方| 如何胜百家乐官网的玩法技巧和规则| 大发888可靠吗| 欢乐谷百家乐官网的玩法技巧和规则| 博盈注册| 高淳县| 奔驰百家乐可信吗| 网上百家乐官网真的假的| 百家乐官网网站制作| 新澳门百家乐的玩法技巧和规则| 新时代百家乐官网娱乐城| 博彩技巧| 威尼斯人娱乐城免费注册| 博彩百家乐官网软件| 千亿娱乐城注册| 成都百家乐官网牌具| 赌百家乐官网的体会| 百家乐破解赌戏玩| 风水24山向哪些不能兼| 收藏| 大发888m摩卡游戏| 网上的百家乐是真是假| 大发888娱乐场下载 制度| 百家乐遥控洗牌器| 华人百家乐官网博彩论| 新世百家乐的玩法技巧和规则| 百家乐官网77scs官网| 百家乐官网比赛技巧| 包赢百家乐官网的玩法技巧和规则| 金钱豹娱乐| 大发扑克娱乐场| 重庆百家乐官网的玩法技巧和规则 | tt娱乐城开户| 大发888客服电话 在线| 财神百家乐的玩法技巧和规则 | 澳门赌百家乐官网的玩法技巧和规则 |